Cell Death Pathways in Parkinson's Disease: Role of Mitochondria
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease and is characterized pathologically by selective loss of nigrostriatal dopaminergic neurons and the formation of Lewy bodies. Although in the majority of cases the cause of PD is unknown, mitochondrial dysfunction, environmental toxins, oxidative stress, and abnormal protein accumulation may all be involved in disease pathogenesis. The discovery of genes causing rare familial forms of PD (including alpha-synuclein, parkin, DJ-1, PINK1, and LRRK2) has shed light on our understanding of the molecular mechanisms of the development of the disease. Further studies from transgenic or toxin-induced experimental models have also provided insights into the etiology of human disease. Recently, accumulating evidence has suggested that mitochondrial dysfunction is one of the key players in molecular cell death pathways of PD. In this review, we provide an overview of the role of mitochondria in the pathogenesis of both sporadic and familial forms of PD. We also discuss the links between different pathways and highlight novel therapeutic opportunities which target mitochondria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 2×
“Mutations in the parkin gene were found in autosomal recessive early-onset PD (70), and parkin mutations are relatively common (accounting for *50% of all autosomal recessive PD cases) (133).”
Mitochondria: Dynamic Organelles in Disease, Aging, and Development
Chan, D. C. (2006) · Cell · doi:10.1016/j.cell.2006.06.010 · Cited by 1,987 · cited 1×
“The balance between fusion and fission not only determines the morphology of mitochondria in cells but also has a significant effect on mitochondrial function (23).”
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 1×
“In Drosophila PINK1 knockout models, motor deficits including abnormal wing posture, rigidity, flight impairment, and reduced climbing ability have been reported and some of the motor phenotypes were progressive with age (26, 112, 164).”
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 3×
“In addition, cell loss was also found in the thoracic indirect flight muscles (173), and swollen mitochondria were seen in the muscle fibers as well as in surviving DAergic neurons (112).”
Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A
Züchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J., et al. (2004) · Nature Genetics · doi:10.1038/ng1341 · Cited by 1,572
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“In two studies using quantitative single cell techniques, high levels of mtDNA deletions were detected in the substantia nigra neurons in both aged controls and PD patients, with a slightly increased trend in PD individuals (12, 75).”
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“Glial cells are also a host of ROS when they are activated (76, 171).”
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“Subcellularly, LRRK2 is mostly associated with the cytoplasmic membrane and has also been reported to be associated with mitochondrial outer membrane fractions (46, 141, 167), suggesting a role for LRRK2 in mitochondrial function.”
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 1×
“A later study from Shults and colleagues showed that co-enzyme Q10 supplementation could slow the motor functional decline in patients with early PD (135).”
Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913 · cited 1×
“Intriguingly, although a mild nonprogressive motor deficit, reduced synaptic excitability, and increased striatal extracellular dopamine concentrations were reported in young parkin knockout mice (49, 61); no loss of DAergic neurons or inclusion formations were described.”
The PINK1/Parkin pathway regulates mitochondrial morphology
Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., & Pallanck, L. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709336105 · Cited by 885
Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.-W., Yang, L., Beal, M. F., Vogel, H., & Lu, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602493103 · Cited by 798
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Self-citationLoss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress
Gautier, C. A., Kitada, T., & Shen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802076105 · Cited by 698 · cited 1×
“More recently, reduced mitochondrial complex activities, and increased sensitivity to oxidative stress have been detected in the same mice (42).”
Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619 · cited 1×
“In primary cortical neuron cultures, overexpression of some LRRK2 mutants (R1441C, Y1699C, or G2019S) can lead to neuronal degeneration (52, 140, 141).”
PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1
Pridgeon, J. W., Olzmann, J. A., Chin, L.-S., & Li, L. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050172 · Cited by 596 · cited 2×
“Most reports have indicated that PINK1 localizes subcellularly in the inner membrane of mitochondria (41, 122, 136), the mitochondrial intermembrane space (122, 136), and=or the outer mitochondrial membrane (41, 178).”
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4042-03.2004 · Cited by 587
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573 · cited 2×
“In toxin-induced animal models, proteasomal inhibition can lead to loss of nigral DAergic neurons (91, 92, 176), although there is still a debate as to whether these are good PD models because some reports failed to reproduce these observations (87).”
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 1×
“Another randomized, double blind, futility clinical trial in early PD patients also could not reject creatine as futile (102).”
BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346 · cited 1×
“Interestingly, deficiency in the substantia nigra and platelets has been consistently detected by several groups (77, 85, 131), whereas in the skeletal muscle the results are less definitive (85, 115, 152).”
PINK1 protein in normal human brain and Parkinson's disease
Gandhi, S. (2006) · Brain · doi:10.1093/brain/awl114 · Cited by 342 · cited 3×
“In mammalian brains, PINK1 is uniformly expressed, with highest expression levels found in the cell bodies of neurons and glia (41, 153).”
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05088.2003 · Cited by 337
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002455 · Cited by 316 · cited 2×
“More recently, it has been suggested that deficiency of a PDassociated gene (PINK1) can lead to cell death via the mitochondrial mediated apoptosis (Bax translocation to mitochondria, activation of caspase-9=-3 and PARP) in longterm culture of human DAergic neurons (170).”
Self-citationBeal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256
Cited by
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease
Martinez, T. N., & Greenamyre, J. T. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4033 · Cited by 266
Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205
“The pathogenesis of Parkinson’s involves nigrostriatal toxicity that may be linked to mitochondrial dysfunction or oxidative stress (for review, see Yao and Wood, 2009; Surendran and Rajasankar, 2010).”
BackgroundCookson, M. R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009415 · Cited by 170
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
Metadata
- Authors
- Yao, Z., & Wood, N. W.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2009-09
- Volume
- 11
- Issue
- 9
- Pages
- 2135-2149
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1968882667
- Cited by
- 80
- References
- 28
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.